Journals
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 3 of 3
2015-03-20 [p.2261]
Q-1020 — Mr. Rankin (Victoria) — With regard to Health Canada and the regulation of pharmaceutical manufacturing companies for the last ten years: (a) how many companies inspected in Canada have received a “proposal to suspend” letter, broken down by year; (b) how many companies inspected in Canada have received an “immediate suspension,” broken down by year; (c) how many companies inspected in Canada that were not sent a “proposal to suspend” letter or subject to a suspension has Health Canada worked with following an inspection to bring about compliance, broken down by year; (d) how many companies inspected in Canada have been subject to a re-inspection within six months, broken down by year; (e) how many companies inspected internationally have received a “proposal to suspend” letter, broken down by year; (f) how many companies inspected internationally have received an “immediate suspension,” broken down by year; (g) how many companies inspected internationally that were not sent a proposal to suspend letter or subject to a suspension has Health Canada worked with following an inspection to bring about compliance, broken down by year; (h) how many pharmaceutical manufacturing companies inspected internationally have been subject to a re-inspection within six months, broken down by year; (i) how many Import Alerts has Health Canada issued with regard to non-compliant health products, broken down by year; (j) which companies have been subject to an Import Alert; (k) how many voluntary quarantine requests has Health Canada issued, broken down by year; (l) which companies have been subject to a voluntary quarantine request; (m) how many “Notice of Intent to Suspend” letters have been issued to clinical trials, broken down by year; (n) how many “immediate suspensions” has Health Canada issued to clinical trials, broken down by year; (o) how many complaints have been received regarding off-label prescriptions of drugs, broken down by year; and (p) how many cases has Health Canada referred to the Public Prosecution Service of Canada for off-label prescriptions of drugs? — Sessional Paper No. 8555-412-1020.
2015-01-27 [p.2039]
— by Ms. Duncan (Etobicoke North), one concerning health care services (No. 412-4762);
2015-01-26 [p.2010]
Q-888 — Ms. Davies (Vancouver East) — With regard to Health Canada: for the last ten years, (a) how many drug safety inspectors has Health Canada employed, broken down by year; (b) how many inspections of pharmaceutical manufacturing companies has Health Canada conducted within Canada, broken down by year; (c) how many pharmaceutical manufacturing companies inspected within Canada have received a warning letter or citation from Health Canada, broken down by year; (d) how many pharmaceutical manufacturing companies inspected within Canada have had penalties imposed, broken down by year; (e) how many pharmaceutical manufacturing companies inspected within Canada have been subject to a ban, broken down by year; (f) how many inspections of pharmaceutical manufacturing companies has Health Canada conducted internationally, broken down by year; (g) how many pharmaceutical manufacturing companies inspected internationally have received a warning letter or citation from Health Canada, broken down by year; (h) how many pharmaceutical manufacturing companies inspected internationally have had penalties imposed, broken down by year; (i) how many pharmaceutical manufacturing companies inspected internationally have been subject to a ban, broken down by year; (j) how many notices of violation concerning companies operating in Canada has Health Canada received from foreign regulators, broken down by year; (k) how many pharmaceutical manufacturing companies has Health Canada inspected because of a notification received from a foreign regulator, broken down by year; (l) how many clinical trials has Health Canada inspected, broken down by year; (m) how many clinical trials received a warning letter or citation from Health Canada following an inspection, broken down by year; (n) how many clinical trials have been shut down by Health Canada following an inspection, broken down by year; (o) how many investigations has Health Canada conducted regarding promotion of off-label prescription of drugs by pharmaceutical companies, broken down by year; (p) how many fines or penalties has Health Canada levied for off-label promotions, broken down by year; (q) how many reports of side effects relating to off-label prescriptions of pharmaceuticals has Health Canada received, broken down by year; and (r) when will Health Canada begin including side effects related to off-label prescriptions in its public database? — Sessional Paper No. 8555-412-888.
Results: 1 - 3 of 3

Export As: XML CSV RSS

For more data options, please see Open Data